Antibacterial activity of the novel oxazolidinone contezolid (MRX-I) against Mycobacterium abscessus

Objective To evaluate contezolid (MRX-I) antibacterial activity against Mycobacterium abscessus in vitro and vivo to assess whether MRX-I treatment can prolong survival of infected zebrafish. Methods inhibitory M. was assessed by injecting into zebrafish with green fluorescent protein-labelled . Thereafter, were treated azithromycin (AZM), linezolid (LZD) or then maximum tolerated concentrations (MTCs) drugs determined based on growth inhibition using one-way ANOVA. Linear trend analysis CFU counts fluorescence intensities (mean ± SE values) performed detect linear relationships between MRX-I, AZM LZD these parameters. Results anti- minimum concentration (MIC) MTC 16 μg/mL 15.6 μg/mL, respectively. MTC-treated significantly lower than respective group (whole-body: 439040 3647 vs. 509184 23064, p < 0.01); head: 74147 2175 95996 8054, 0.05). As increased from 0.488 whole-body, head heart decreased. Statistically insignificant differences the rate (78.33%) corresponding rates 62.5 μg/mL-treated (88.33%, > 0.05) (76.67%, observed. Conclusion effectively inhibited prolonged when administered -infected zebrafish, thus demonstrating that holds promise as a clinical for human infections.